Davern Capital Partners, LP: ROYALTY PHARMA PLC (RPRX): Quarterly 13F Position History
As of Q1 2026, Davern Capital Partners, LP reported 520,009 shares of ROYALTY PHARMA PLC (RPRX), worth $24.9M and representing 6.8% of its 13F equity book. Quarter-over-quarter share count change: 320,641 (-38.1%) . The position first appeared in Q4 2025 and has been disclosed across 2 13F-HR filings in Pactolio's tracked window.
- 520,009Shares Held (Latest Filing)
- $24.9MReported Market Value (Latest Filing)
- 6.8%Portfolio Weight (% of 13F Equity Book)
- 320,641Quarter-over-Quarter Share Change
- -$7.5MQuarter-over-Quarter Value Change
- 840,650Peak Reported Shares (Historical)
Recent initiation: Davern Capital Partners, LP first reported RPRX on the Q4 2025 filing — fewer than three quarters of history are available.
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 2 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 520,009 | 320,641 | -38.1% | $24.9M | 6.8% | $48.0 |
| Q4 2025 | 840,650 | — | — | $32.5M | 10.5% | $38.6 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Davern Capital Partners, LP first disclose a RPRX position in 13F-HR filings?
Davern Capital Partners, LP first reported ROYALTY PHARMA PLC (RPRX) on its 13F-HR filing for the period ending 2025-12-31 (Q4 2025). The position has appeared on 2 reported quarters within Pactolio's tracked window.
What was Davern Capital Partners, LP's most recent quarter-over-quarter share-count change in RPRX?
Between Q4 2025 and Q1 2026, Davern Capital Partners, LP reduced its RPRX position by 320,641 shares (-38.1%), leaving 520,009 shares at a market value of $24.9M.
Does the implied price-per-share represent Davern Capital Partners, LP's cost basis in RPRX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.